USTR Opens Comment Docket on Suspension of Action in Section 301 Investigation of China’s Targeting of the Maritime, Logistics, and Shipbuilding Sectors for Dominance - U.S. Trade Representative
WASHINGTON — Today, the Office of the U.S. Trade Representative (USTR) announced a public comment process on the proposed suspension of the action in the Section 301 Investigation of China’s Targeting of the Maritime, Logistics, and Shipbuilding Sectors for Dominance.
On November 1, 2025, the White House announced a historic trade and economic deal reached between President Trump and President Xi Jinping of China. Pursuant to this deal, the United States would suspend for one year, beginning on November 10, 2025, the responsive actions taken in this investigation. The United States also will negotiate with China pursuant to Section 301 regarding the issues raised in this investigation. While taking these actions, the United States will continue its domestic efforts and its discussions with key allies and partners on revitalizing American shipbuilding.
The U.S. Trade Representative, at the direction of the President, is therefore proposing to suspend for one year, beginning on November 10, 2025, the responsive actions taken in this investigation.
As explained in a formal notice, to be assured consideration, interested persons should submit written comments by November 7, 2025, at 5:00 p.m., Eastern Standard Time.
Comments in response to this notice can be submitted or accessed here.
________________________________________________________________________________
In the News
• China and ASEAN, hit by US tariffs, sign upgraded free trade pact [Rueters]
• Trump says his tariffs will help American businesses. So why are they suing? [USA Today]
• Borderlands Mexico: New customs regulation could slow cross-border trades [Freight Waves]
• CEO challenging Trump at Supreme Court could trigger wave of tariff refunds: "I definitely want my money back" [CBS News]
________________________________________________________________________________
Import Alerts (FDA):
• [11/06/2025] Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
• [11/06/2025] "DETENTION WITHOUT PHYSICAL EXAMINATION OF REFRIGERATED (NOT FROZEN WITH PROPER LABELING) RAW FISH AND FISHERY PRODUCTS IN REDUCED OXYGEN PACKAGING DUE TO THE POTENTIAL FOR CLOSTRIDIUM BOTULINUM TOXIN PRODUCTION"
• [11/04/2025] Detention Without Physical Examination of New Tobacco Products, Other Than ENDS, Without Required Marketing Authorization"
• [11/04/2025] "Detention Without Physical Examination of Human and Animal Foods Imported from Foreign Suppliers by Importers Who Are Not in Compliance with the Requirements of the Foreign Supplier Verification Program (FSVP) Regulation"
• [11/04/2025] "Detention Without Physical Examination Of Finished Dosage Form Drug Products, Active Pharmaceutical Ingredients, and Inactive Ingredients for Potentially Hazardous Microbiological Contamination"
• [11/04/2025] "Detention Without Physical Examination of Food Products Due to the Presence of Salmonella"
• [11/04/2025] "Detention without Physical Examination of Processed Human and Animal Foods for Pesticid es"
• [11/04/2025] "Detention Without Physical Examination Of Cosmetics That are Adulterated and/or Misbranded Due to Color Additive Violations"
• [11/04/2025] "Detention Without Physical Examination and Guidance of Foods Containing Illegal and/or Undeclared Colors."
• [11/03/2025] Detention Without Physical Examination of Certain Human Food Products From Certain Regions In Indonesia Subject To The Requirement of Import Certification Per Section 801(q)
• [11/03/2025]"Detention Without Physical Examination Of Ready-To-Eat Human Food Products That Appear To Have Been Prepared, Packed, Or Held Under Insanitary Conditions"
• [11/03/2025] DETENTION WITHOUT PHYSICAL EXAMINATION OF FOODS DUE TO HEAVY METAL (TOXIC ELEMENT) CONTAMINATION
• [11/03/2025] "Detention Without Physical Examination of New Tobacco Products, Other Than ENDS, Without Required Marketing Authorization"
• [11/03/2025] Detention Without Physical Examination of Imported Food Products That Appear to Be Misbranded
• [11/03/2025] "DETENTION WITHOUT PHYSICAL EXAMINATION OF PAPAYA FROM MEXICO"
• [11/03/2025] Detention Without Physical Examination of Human and Animal Food Products from Foreign Establishments Refusing FDA Inspection
• [11/03/2025] Detention Without Physical Examination of Food Products Containing Undeclared Added Sulfiting Agents
• [11/03/2025] "Detention Without Physical Examination of Food Products Due to the Presence of Salmonella"
• [11/03/2025] "Detention without Physical Examination of Processed Human and Animal Foods for Pesticides"
• [11/03/2025] "Detention Without Physical Examination Of Raw Agricultural Products for Pesticides"
• [10/31/2025] Detention Without Physical Examination of Certain Human Food Products From Certain Regions In Indonesia Subject To The Requirement of Import Certification Per Section 801(q)
• [10/31/2025] "DETENTION WITHOUT PHYSICAL EXAMINATION OF PAPAYA FROM MEXICO"
• [10/312025] Detention Without Physical Examination of Human and Animal Food Products from Foreign Establishments Refusing FDA Inspection
• [10/31/2025] "Detention Without Physical Examination of Seafood Products Due to Nitrofurans"
• [10/31/2025] "Detention Without Physical Examination of Devices without Approved PMA's or IDE's and Other Devices Not Substantially Equivalent or Without a 510(k)"
• [10/31/2025] "Detention Without Physical Examination and Guidance of Foods Containing Illegal and/or Undeclared Colors."
________________________________________________________________________________
The Department of Commerce Announces American AI Exports Program Implementation - Department of Commerce
WASHINGTON, D.C. — The U.S. Department of Commerce’s International Trade Administration (ITA) today announced the implementation of the American AI Exports Program, following President Donald J. Trump’s July 23 Executive Order on Promoting the Export of the American AI Technology Stack.
Under President Trump’s direction, the Department of Commerce is launching a full-stack AI export promotion program to advance America’s global leadership in AI. The program will select industry-led export packages that will include AI hardware, software, models, and applications across industry sectors for promotion to countries and regions around the world.
The implementation of the American AI Exports Program commences with industry engagement, including a Request for Information (RFI) to invite public comments from U.S. and global technology companies to shape the Program, understand industry needs, and ensure that policy outcomes are met.
To facilitate connections between interested U.S. companies and trusted foreign buyers, the Department of Commerce will launch a new website, AIexports.gov, and establish an integrated American AI export team. To provide a global presence for the Program, the International Trade Administration will leverage its expertise in export promotion through its commercial service officers across the United States and the globe. The Department of Commerce will also partner with the Department of State to leverage its foreign service officers and ambassadors in support of this effort around the world.
Informed by the responses to the RFI, the American AI Exports Program will include a public call for proposals from industry-led consortia to export full-stack AI technology packages. Proposals submitted for inclusion under the Program will be evaluated in consultation with the Secretary of State, the Secretary of War, the Secretary of Energy, and the Director of the Office of Science and Technology Policy. Once approved, full-stack AI packages will be supported through the interagency Economic Diplomacy Action Group for qualified export opportunities.
The Department of Commerce will release additional Program announcements and features as implementation continues.
Learn more about the President’s AI Action Plan here.
Read the President’s Executive Order on AI exports here.
________________________________________________________________________________
FDA Warns Companies Over Illegal Marketing of Botox and Related Products - Food & Drug Administration
The U.S. Food and Drug Administration issued 18 warning letters to owners of websites illegally marketing unapproved and misbranded botulinum toxin products, commonly called Botox. The agency is aware of adverse events associated with unapproved and misbranded botulinum toxin products, including botulism symptoms.
Botulinum toxin products are injectable drugs that block nerve activity in muscles, temporarily reducing muscle movement. They are used for cosmetic purposes like reducing facial wrinkles as well as to treat medical conditions such as chronic migraines and muscle stiffness.
“Unapproved and misbranded Botox products carry serious health risks. Today we’re taking action to protect American consumers and prevent online entities from selling these dangerous products,” said FDA Commissioner Marty Makary, M.D., M.P.H.
FDA-approved botulinum toxin products carry a boxed warning, the agency’s most serious warning, indicating the drug carries a significant risk of serious or life-threatening side effects. The boxed warning indicates the product may cause symptoms of botulism, which attacks the body’s nerves and causes muscle weakness that can lead to difficulty breathing and even death.
There are several FDA-approved botulinum toxin products, such as Botox, which are only available with a prescription from a licensed health care professional. Patients should ensure they only receive these products from a provider who is licensed and trained to administer such injections. Additionally, patients should only receive these injections if the product is obtained from an authorized source. Products purchased from unauthorized sources may be unapproved, misbranded, adulterated, counterfeit, contaminated, improperly stored and transported, ineffective and/or unsafe.
Seek immediate medical care if you have symptoms of botulism, including trouble swallowing or breathing, after receiving a botulinum toxin product injection.
The FDA issued warning letters to:
acecosm.com
aesthetic-essentials.com
celestapro.com
cosmenic.net
cosmo-korea.com
derma-solution.com
dermaxshop.com
ellepharm.com
estaderma.com
filleroutlet.com
glamderma.com
glowface.store
glownestbeauty.com
koreafillerexperts.com
koreanfillers.com
maypharm.net
meamoshop.com
mjsmedicals.com
Health care professionals and consumers should report adverse events to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program